The hepatorenal protective effects of silymarin in cancer patients receiving chemotherapy: a randomized, placebo-controlled trial.
- 2024-09-04
- RCT · n = 100
- BMC complementary medicine and therapies 24(1)
- Safoora Sadat Erfanian
- Hourieh Ansari
- Shaghayegh Haghjooy Javanmard
- Zahra Amini
- Ali Hajigholami
- PubMed: 39232773
- DOI: 10.1186/s12906-024-04627-7
- High evidence
- Large Human Trial
- Clinical
Silymarin showed significant effects on liver enzymes in the levels of ALP and bilirubin (P < 0.05)
- Effect
- Beneficial
- Effect size
- Small
- Significant
- Yes
- Dose
- 140 mg daily